Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and D-fenfluramine in rats.
The role of brain serotonin in regulating prolactin (PRL) secretion has been investigated by studying the effect of quipazine and D-fenfluramine, two serotonin-like drugs, on plasma PRL levels under various experimental conditions. Quipazine (5, 10 and 20 mg/kg i.p.) and D-fenfluramine (5, 7.5 and 10 mg/kg i.p.) induced dose-related increases in plasma PRL levels in male rats. Intraventricular injection of 5,7-dihydroxytryptamine (5,7-DHT) or electrolytic lesion of the nucleus raphe medianus (MR), which caused a marked and selective depletion of hypothalamic serotonin levels, significantly reduced the PRL-releasing effect of both quipazine and D-fenfluramine. These results suggest that the effect of these drugs on PRL release is mediated through a serotonergic mechanism in the brain.
D015116:5,7-Dihydroxytryptamine / Q000494:pharmacology*; D000818:Animals; D001933:Brain Stem / Q000502:physiology*; D004102:Dihydroxytryptamines / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005277:Fenfluramine / Q000494:pharmacology*; D007031:Hypothalamus / Q000187:drug effects / Q000502:physiology; D008297:Male; D011388:Prolactin / Q000378:metabolism*; D011804:Quinolines / Q000494:pharmacology*; D011814:Quipazine / Q000494:pharmacology*; D011903:Raphe Nuclei / Q000502:physiology*; D051381:Rats
D004102:Dihydroxytryptamines; D011804:Quinolines; D005277:Fenfluramine; D015116:5,7-Dihydroxytryptamine; D011814:Quipazine; D011388:Prolactin